Artificial Intelligence in COPD
Artificial Intelligence in COPD is transforming disease management, from underdiagnosis to treatment guidance. Discover how machine learning clusters patients, predicts outcomes, and optimizes healthcare resources.
Artificial Intelligence in COPD is transforming disease management, from underdiagnosis to treatment guidance. Discover how machine learning clusters patients, predicts outcomes, and optimizes healthcare resources.
Discover the normal ranges of fractional exhaled nitric oxide (FeNO) across different age groups in a respiratory healthy population. Based on 2,251 participants, this study identifies factors like age, body height, and eosinophil counts that influence FeNO levels.
Explore the causes of reduced FEV1 in early adulthood, with data from Lifelines and BAMSE cohorts. Findings highlight PRISm and airflow limitation origins, early identification in childhood, and differentiated clinical implications.